Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (299.5), the stock would be worth ¥15.71 (62% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 785.6 | ¥41.22 |
0%
|
| 3-Year Average | 299.5 | ¥15.71 |
-62%
|
| 5-Year Average | 82.8 | ¥4.34 |
-89%
|
| Industry Average | 25 | ¥1.31 |
-97%
|
| Country Average | 18.3 | ¥0.96 |
-98%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Hebei Changshan Biochemical Pharmaceutical Co Ltd
SZSE:300255
|
37.9B CNY | 785.6 | -125.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 47.8 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 22.3 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 19.3 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 14.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 16.7 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.5 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 12.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 8.2 | 16.4 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 9.8 |
| Median | 18.3 |
| 70th Percentile | 36.5 |
| Max | 266 666.7 |
Other Multiples
Hebei Changshan Biochemical Pharmaceutical Co Ltd
Glance View
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates as a key player in the global pharmaceutical industry, with a focused mission of advancing healthcare through innovative biochemical products. Founded in the heartland of China's Hebei province, the company has carved out a niche for itself by specializing in the production of heparin, a critical anticoagulant used in preventing and treating blood clots. Through state-of-the-art biotechnology and substantial R&D investments, Changshan Biochemical has mastered the complex extraction and refining processes that transform raw materials, often sourced from porcine intestinal mucosa, into these essential, life-saving pharmaceuticals. This scientific prowess is not just an end in itself; it represents the backbone of the company's business model, driving both their product portfolio and revenue streams. The company's success is intricately tied to its ability to integrate vertically and scale efficiently, which enhances operational agility and cost management. Such vertical integration involves controlling multiple stages of production—from raw material sourcing and synthesis to finished product distribution—ensuring consistent quality and supply. Moreover, Hebei Changshan's strategic emphasis on innovation allows it to develop new formulations and applications for its biochemical products, expanding its market reach both domestically and internationally. Revenue generation is largely derived from hospital sales, direct pharmaceuticals sales, and partnerships with other biotech firms. By leveraging its biochemical expertise and maintaining robust industry relationships, Changshan Biochemical not only secures its financial performance but also positions itself as a dependable partner in the global healthcare supply chain.